Fig. 3: Tideglusib treatment improves muscle performance in 10–12 week old C57 mdx mice.
a, b Twitch and tetanic (160 Hz) specific force production (mN/mm2) is unchanged in the EDL muscle with tideglusib treatment (n = 5 per group). c Tideglusib treatment improves EDL muscle fatigue with a rightward shift in the fatigue curve in 10-12 week old C57 mdx mice (n = 5 per group). d Hangwire impulse is greater in tideglusib-treated mdx mice, which approached statistical significance (p = 0.09) (vehicle, n = 6 and tideglusib, n = 7). e Serum creatine kinase (CK) (U/L) is not different between vehicle and tideglusib-treated mdx mice (n = 8 per group). f Energy expenditure is greater in tideglusib-treated mdx mice with this effect approaching significance (p = 0.09), across light, dark, and daily cycles (vehicle, n = 8 and tideglusib, n = 7). g Tideglusib lowers the respiratory exchange ratio (RER) in C57 mdx mice (vehicle, n = 8 and tideglusib, n = 7). h Tideglusib elevates cage ambulation (meters traveled) in C57 mdx mice (vehicle, n = 8 and tideglusib, n = 7). i–l Insulin tolerance tests and corresponding area-under-the-curve (AUC) analysis, baseline glucose levels and % decline in blood glucose in mdx-vehicle and mdx-tideglusib mice (n = 8 per group). Glucose traces are displayed relative to baseline glucose levels. AUC was obtained from the normalized traces. There is no difference in the AUC, basline blood glucose (mM), and % decline in blood glucose. For (a, b, d, e, j, k, and l), a two-tailed Student’s t-test was used. For (c, f, g, and h), a two-way ANOVA was used to assess the main effects of time and tideglusib treatment. For (i), a two-way repeated ANOVA was used for the insulin tolerance test. Significant main effects and interaction terms are denoted in the text above. All values are mean ± SEM.
